NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer

NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer

Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic challenges. NR4A1 plays key roles in processes associat...

Full description

Bibliographic Details
Main Authors: Yu Cheon Kim, Clara Yuri Kim, Ji Hoon Oh, Myoung Hee Kim
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cells
Subjects:
NR4A1
ERK signaling pathway
tamoxifen resistance
breast cancer
Online Access:https://www.mdpi.com/2073-4409/10/7/1633

Similar Items

Similar Items